What are H2 blockers, really?
H2 blockers — full name histamine H2-receptor antagonists — are a family of drugs that lower how much acid your stomach makes. They do it by sitting on a specific receptor in the stomach lining and quietly blocking one of the signals that switches acid production on. The names you'll meet are famotidine (Pepcid), ranitidine (Zantac), nizatidine (Axid), and the granddaddy of them all, cimetidine (Tagamet). Famotidine is the one still in everyday use; the others have mostly faded for reasons we'll get to.
For a couple of decades this class was the big deal. Cimetidine arrived in 1976 and famotidine followed in the mid-1980s, and before proton pump inhibitors came along they were the gold standard for healing peptic ulcers. Then PPIs showed up, hit acid harder, and took the top spot. Today H2 blockers live mostly in two roles: an over-the-counter option for the occasional bout of heartburn, and a second-string player in chronic reflux where a PPI is doing the heavy lifting.
The single most useful thing to hold onto: an H2 blocker doesn't repair anything. It turns down acid production a notch. The underlying reflux or irritation is still there; there's just less acid around to make it hurt.
How they work — the simple version
Picture the cell that makes stomach acid — the parietal cell — as a valve with three separate levers feeding into it. Pull any lever and acid starts flowing. Pull all three and you get a full stream.
The three levers are three different chemical signals:
- Histamine, which docks onto the H2 receptor (this is the lever H2 blockers grab).
- Gastrin, a hormone released when food shows up.
- Acetylcholine, the nervous-system signal — the one that fires when you smell dinner or even think about it.
All three converge on the same final piece of machinery: the proton pump (its formal name is the H⁺/K⁺-ATPase), the little molecular engine that actually pushes acid out into the stomach. This whole chain — three signals, one output — was mapped out in detail by Schubert and Peura in Gastroenterology (2008), and it's the key to understanding the entire acid-reducer aisle.
Here's where the two big drug classes part ways. An H2 blocker grabs one lever — the histamine one — and holds it down. That meaningfully reduces both your background acid and the surge you get from a meal, because histamine is a major amplifier. But the other two levers, gastrin and acetylcholine, can still pull. So acid output drops a lot, not all the way. A PPI, by contrast, ignores the levers entirely and jams the valve itself — the pump. Once the pump is off, it doesn't matter how hard the levers pull. That's the whole reason PPIs hit harder, and why a PPI usually wins for serious, persistent acid disease.
Two practical quirks follow from this. First, H2 blockers come on faster than PPIs — relief in roughly 30 to 60 minutes, versus a few hours to a few days for a PPI to reach full strength. So for a flare you can feel coming, they're quick. But they have a lower ceiling — they simply can't suppress acid as completely. Second, and this surprises people: with continuous daily use the effect fades. Over a few weeks the body adapts, ramping up its histamine receptors to compensate (this is called tolerance). The same dose that worked beautifully in week one can feel weaker by week three. PPIs don't really do this. So an H2 blocker is often at its best as an as-needed tool rather than a daily forever-pill.
What else they do to your body, beyond reducing acid
Start from the mechanism and the side effects stop looking random. Most of them come from one of two facts: the receptor these drugs block lives in places besides your stomach, and one old member of the family meddles with the liver's drug-processing machinery.
Cimetidine, the troublemaker. The original H2 blocker has two habits the newer ones dropped. It's weakly anti-androgenic — it nudges down male hormone signaling — which, with long-term use, can cause breast tissue growth in men (gynecomastia). More importantly, cimetidine is a potent inhibitor of the liver's cytochrome P450 enzymes (CYP1A2, 2C9, 2D6, 3A4 — the workhorses that break down a long list of medications). Block those enzymes and other drugs pile up in the blood instead of clearing normally. That's why cimetidine famously tangles with warfarin (a blood thinner), theophylline (an old asthma drug), tricyclic antidepressants, and many more. Famotidine and nizatidine don't meaningfully do this, which is a big part of why cimetidine is rarely chosen today.
The brain. H2 receptors aren't only in your stomach — there are some in your brain too. Block enough of them, especially in an older person or someone whose kidneys clear the drug slowly, and you can occasionally get confusion, agitation, or even hallucinations. It's uncommon, it's almost always reversible once the drug stops, and it's far more likely in the elderly and the seriously ill. Cantu and Korek catalogued these central-nervous-system reactions across the whole class in the Annals of Internal Medicine (1991), and cimetidine again came out as the worst offender.
The ranitidine NDMA story. In 2020 the FDA requested removal of ranitidine because the NDMA impurity could increase during storage. On 24 November 2025 it approved reformulated tablets with revised storage requirements. This does not make old stock suitable for use or establish availability in every country. Some nizatidine products also had recalls; check the current product information (FDA, 2020; 2025).
The ordinary stuff. Beyond all that, plain H2 blockers like famotidine are remarkably well tolerated. When side effects show up they're mild and infrequent: headache, constipation or diarrhea, a bit of dizziness. For most people, most of the time, that's the whole list.
What people usually take with them, and why
H2 blockers rarely work entirely alone. Here's the company they keep, and what the guidelines actually say.
Antacids, for the first ten minutes. An H2 blocker takes 30 to 60 minutes to start working. An antacid (Tums, Maalox, Gaviscon) works in minutes — but it does something different. Antacids don't reduce how much acid you make; they chemically neutralize the acid that's already there. So the two are natural partners for a flare: the antacid handles right now, the H2 blocker handles the next several hours. Different jobs, no conflict.
Bedtime famotidine on top of a daily PPI. This is the most evidence-backed combination in the class. Some people on a once-daily PPI still get a surge of acid overnight — "nocturnal acid breakthrough." Adding an H2 blocker at bedtime can blunt that nighttime surge, taking advantage of the fact that H2 blockers are especially good at quieting the background, fasting acid the night produces. The 2022 American College of Gastroenterology guideline for reflux disease (Katz et al.) discusses exactly this as an add-on option for the right patients. Note the tolerance catch from earlier: because the effect can fade with continuous use, this trick often works better taken as needed than every single night.
H. pylori treatment — a job they've mostly lost. H. pylori is the stomach bacterium behind a big share of ulcers. Older eradication regimens sometimes leaned on H2 blockers for acid suppression, but modern triple and quadruple therapies are built around PPIs, which suppress acid harder and help the antibiotics work better. H2 blockers have largely been displaced here.
One thing they are NOT for: NSAID ulcer protection. This matters. If someone takes NSAIDs long-term and needs their stomach protected from ulcers, the guidelines are clear that a PPI is the right shield, not an H2 blocker. The American College of Gastroenterology guideline on preventing NSAID ulcer complications (Lanza et al., 2009) explicitly favors PPIs for this purpose, and comparative studies back that up (Lin et al., Gastroenterology, 2011). An H2 blocker is simply weaker for this specific job. Don't treat them as interchangeable here.
A word on interactions: with the modern H2 blockers (famotidine, nizatidine) drug interactions are minor. Cimetidine is the glaring exception — as covered above, it interferes with the liver clearance of a long list of medications. If you're on warfarin, theophylline, certain antidepressants, or really any drug with a narrow safety margin, cimetidine is the H2 blocker to avoid, and that's a conversation for a pharmacist, not a guess.
Red flags — when to call a doctor
H2 blockers are easy to buy and easy to take, which is exactly why it's worth knowing the symptoms that mean stop self-treating and get checked. Reaching for another tablet is the wrong move when any of these show up.
- Black, tar-like stools (melena), or vomiting blood or what looks like coffee grounds. These are signs of bleeding in the upper gut. Emergency — not a "see how tomorrow goes."
- Unexplained weight loss, trouble swallowing, or food sticking alongside heartburn. These are the symptoms doctors use to rule out something more serious, including cancer. They need a look, not a stronger antacid.
- Heartburn that hasn't improved after about two weeks of treatment. An over-the-counter acid reducer is meant for short-term, occasional use. If it isn't working, the problem needs a diagnosis, not a refill.
- New heartburn that starts after about age 55. New acid symptoms later in life deserve a proper evaluation rather than quiet self-medication.
- Confusion, agitation, or hallucinations in an older person on one of these drugs — especially on cimetidine. As covered above, that can be the brain reacting to the medication, and it's a reason to call.
What people get wrong
"H2 blockers and PPIs are basically the same thing." They're not. Both reduce acid, but they hit different targets. An H2 blocker blocks one signal (histamine) into the acid-making cell; a PPI disables the pump that cell uses to actually produce acid. That's why a PPI suppresses acid more completely, and why your doctor might switch you from one to the other rather than just upping the dose.
"Ranitidine was just rebranded." The 2020 withdrawal concerned an impurity, not the name. The US return in 2025 involved reformulation and a new safety assessment. Use only currently authorised products and their storage instructions, after discussing any change with a pharmacist or prescriber.
"H2 blockers are safe to take every day forever for chronic reflux." Two problems. First, tolerance: the effect tends to fade with continuous daily use as your body adapts. Second, for genuine long-term reflux disease, PPIs have the stronger evidence base and don't lose potency the same way (Katz et al., 2022). H2 blockers shine as an occasional or add-on tool, not usually as the sole long-term answer.
"Famotidine treats COVID." This one has a real origin and a disappointing ending. Early in the pandemic, a retrospective study suggested hospitalized COVID-19 patients on famotidine did better (Freedberg et al., Gastroenterology, 2020). It was a signal worth chasing — but later, larger and more rigorous trials didn't confirm a meaningful benefit. So: an interesting lead that didn't pan out, not an established treatment.
"All H2 blockers are interchangeable." Mostly, but cimetidine is dramatically different. It meddles with the liver enzymes that clear a long list of other medications and has mild hormonal effects, neither of which the newer ones share. Swapping cimetidine in for famotidine without checking the rest of someone's medication list can cause real trouble.
"An H2 blocker will protect my stomach from NSAID ulcers." Not the way you'd hope. For NSAID ulcer prevention the guidelines favor PPIs, which are simply more effective for that specific job (Lanza et al., 2009; Lin et al., 2011). An H2 blocker is the weaker shield here, and treating the two as equivalent is exactly the mistake the guidance warns against.